ACE and Hypertension: The prevalence of hypertension has been reported to vary between 17 and 42% in patients treated with sorafenib and between 15 and 47% in those treated with sunitinib.9,10 Anthracyclines, mitotic inhibitors, alkylating agents, proteasome inhibitors, and TKIs have all been linked to cardiotoxicity and symptoms, such as ischemia, arrhythmias, hypertension, LVD, and the symptoms of HF.11 The European Society for Medical Oncology (ESMO) favors the use of angiotensin-converting enzyme (ACE) II inhibitors in asymptomatic patients with LVD who exhibit an ejection fraction of less than 40%.